On July 25, the National Drug, Food and Medical Technology Administration (allowed, A new injectable drug has been approved to treat obesity. But from the laboratory he reported in the last hours that “he is not expected to come.” Argentinian pharmacies before the next 12 months,
is about veggieconsidered a medicine “Revolutionary” For results obtained in clinical studies for the treatment of obesity. Its active principle is semaglutide And it is a product that is heavily promoted by celebrities internationally Elon Musk, Lady Gaga and Kim Kardashian.
The delay in their arrival in the country is due to the provisions of Article 5 of the Permissible Provisions. This section states that The manufacturer must first “request an effective marketing authorization indicating the start date of the import of the first batch”.who must pass “the” check related technology before going on sale”.
Medicine required to reach pharmacies in Argentina go through a lengthy security protocol and inspection by Unmac.
What is Vegovy, the “revolutionary” obesity drug?
The drug Vegovy has become one of the most important novelties for the treatment of obesity around the world. Its clinical indications state that “it is indicated in Combination with a reduced calorie diet and increased physical activity for weight controlIn adults with a body mass index (BMI) “consistent with obesity or overweight”, including weight loss and weight maintenance at least one weight-related comorbidityFor example, abnormal blood glucose (prediabetes or type 2 diabetes mellitus), high blood pressure, dyslipidemia, obstructive sleep apnea, or disease.”
In a conversation with Tellum, Julio Monteiro, nutritionist and president of the Argentine Society of Obesity and Eating Disorders (SAOTA), said: “The drug It is very promising as studies have shown that it has superior weight loss potential For the medicines that we had till now. this is great news For obese people.
A clinical study published by the laboratory on its website shows that patients treated with Vegovy Average weight loss of 15% after 68 weeks of treatment, while those receiving a placebo lost 2.4% of their body weight. On average, people who managed to lose weight regained the weight Lost about 16 kilos in that period.
“Semaglutide is revolutionary for the treatment of obesity and overweight, especially in those who have other metabolic comorbidities such as diabetes or dyslipidemiaMaria Milagros Alico, nutritionist and diabetologist, told Tellum.
Furthermore, he acknowledged that the new drug is part of a “process”.Radical change in obesity treatment«, although we should not lose sight of the fact that the approach should always be “integral”.
“It is not a magic pill, nor is it a solution if it is not accompanied by a comprehensive treatment plan, because Obesity is a very complex disease that requires attention to many areas such as psychological, nutritional and physical activity.“, he insisted.
In this sense, he pointed out that “the wonderful thing is that we are More and More Drugs for the Growing Epidemic of Obesity“, a disease that until recently could only be fought with “physical activity, diet and surgery”.
Both experts agreed that the drug It should be released only with a prescription and treatment should be carried out under strict medical supervision.,
With regard to adverse effects, Alico pointed out that “most are gastrointestinal”. such as nausea or vomiting. “It may give slight headache, some diarrhea or constipation in some patients, but not more,
Both Ruled out that treatment with this drug increases the risk of thyroid tumors and both said Survivors object to its use,
«It does not produce thyroid tumors, but in people who have had a specific cancer, such as the thyroid, medicine is prohibitedSimilar to patients who suffer from acute pancreatitis”, Monteiro concluded.